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Abstract 
Autoimmune disorders are characterized by tissue damage, caused by self‑reactivity of different effectors mechanisms 
of the immune system, namely antibodies and T cells. Their occurrence may be associated with genetic and/or envi‑
ronmental predisposition and to some extent, have implications for fertility and obstetrics. The relationship between 
autoimmunity and reproduction is bidirectional. This review only addresses the impact of pregnancy on autoimmune 
diseases and not the influence of autoimmunity on pregnancy development. Th17/Th1‑type cells are aggressive and 
pathogenic in many autoimmune disorders and inflammatory diseases. The immunology of pregnancy underlies 
the role of Th2‑type cytokines to maintain the tolerance of the mother towards the fetal semi‑allograft. Non‑specific 
factors, including hormonal changes, favor a switch to Th2‑type cytokine profile. In pregnancy Th2, Th17/Th2 and Treg 
cells accumulate in the decidua but may also be present in the mother’s circulation and can regulate autoimmune 
responses influencing the progression of autoimmune diseases.
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Background
Autoimmune diseases include approximately 80 different 
disorders. Although, individually, each autoimmune dis-
ease affects a small number of individuals, as a whole, it 
is estimated that its prevalence is between 7.6 and 9.4 % 
[1]. It is well accepted that a disease can be classified as 
autoimmune if one shows that an immune response to a 
self-antigen causes the disease pathology. Indeed, auto-
immune disorders are characterized by tissue damage, 
caused by self-reactivity of different effectors mecha-
nisms of the immune system, namely antibodies and T 
cells. Their occurrence may be associated with genetic 
and/or environmental predisposition [2, 3] and to some 
extent, have implications for fertility and obstetrics.
The relationship between autoimmunity and repro-
duction seems to be bidirectional. Accordingly, auto-
immune diseases may selectively affect women in their 
reproductive years and conversely pregnancy may affect 
the expression of autoimmune diseases. Thus, autoim-
munity may have an influence on pregnancy outcomes. 
As the matter of fact, Gleicher et al. [4], performed Pub-
Med, Google Scholar and Medline searches for the years 
2000–2010 under various key words and phrases, refer-
ring to effects of autoimmunity/autoimmune diseases on 
pregnancy/pregnancy outcomes/pregnancy rates/repro-
duction/reproductive outcomes/fertility/infertility/fertil-
ity treatments/infertility treatments, and similar terms, 
toward significant impacts of autoimmunity on female 
reproductive success. They reported that autoimmun-
ity not only increases miscarriage risks but also reduces 
female fecundity and infertility treatment success. How-
ever, pregnancy may have an influence on autoimmune 
diseases improvement or worsening. During pregnancy 
many autoimmune diseases go into remission, only to 
flare again in the early post-partum period. For exam-
ple, Graves disease is an autoimmune thyroid disease 
which ameliorates during pregnancy, only to relapse post 
partum.
This review only addresses the impact of pregnancy on 
autoimmune diseases and not the influence of autoim-
munity on pregnancy development.
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Pregnancy is related to T cell mediated‑responses 
towards conceptus
The fact that women can successfully carry a conceptus, 
which is liken to an allograft, to full term without rejec-
tion is one of the most remarkable aspects of pregnancy.
Although conceptus/trophoblast does not express HLA 
class II molecules, it exhibits HLA class I molecules, the 
polymorphic HLA-C molecules, together with the non-
polymorphic HLA-G and HLA-E. For the presence of 
paternal class I HLA-C molecules on the fetal-derived 
trophoblast cells, that invade the maternal decidua basa-
lis, the conceptus has been considered to be a semi-
allograft. After presentation of paternal alloantigens by 
maternal antigen presenting cells (APCs), the maternal 
T cells specific for these alloantigens, [5] could prolifer-
ate and secrete cytokines, promoting the activation of 
allograft rejection or tolerance mechanisms, respectively 
responsible for pregnancy failure or fetal survival.
In fact, on the basis of the profile of cytokines pro-
duced, T helper cells are classified in T helper (Th)1, Th2 
and Th17 cells [6, 7]. CD4+ Th1 cells produce interleu-
kin (IL)-2, tumor necrosis factor (TNF)-β and interferon 
(IFN)-γ and are the main effectors of phagocyte-medi-
ated host defense, which are highly protective against 
infections sustained by intracellular pathogens. On the 
other hand, CD4+  Th2 cells, which are mainly respon-
sible for phagocyte-independent host defense against 
extracellular pathogens, including nematodes, produce 
IL-4 (which together with IL-10 inhibit several mac-
rophage functions and together with IL-13 produced by 
Th2 cells, stimulates IgE antibody production) and IL-5 
(which promotes growth, differentiation and activation of 
eosinophils) [6]. An additional subset of CD4+ T helper 
cells named Th17, which produce IL-17A, IL-17F, IL-21, 
IL-26 and IL-22 [7], is protective against extracellular 
bacteria and may also play a role in inflammation [8]. A 
part of human IL-17A-producing cells were found to also 
produce interferon (IFN)-γ (they are named Th17/Th1) 
and both Th17 and Th17/Th1 exhibit plasticity towards 
Th1 cells in response to IL-12 produced by APCs [8]. 
Another part of the Th17 cells could also produce IL-4 
(they are named Th17/Th2) in response to IL-4 present 
in the microenvironment of these cells or HLA-G5 pro-
duced by trophoblast cells and embryo at feto maternal 
interface [9, 10].
These three types of effector T helper cells play a cen-
tral role in acute allograft rejection and tolerance. IFN-γ 
and IL-17 has been detected in rejecting allografts [11–
13], indicating that some Th1- and Th17-dependent 
effector mechanisms play a central role in acute allograft 
rejection of transplanted tissues [14]. The production of 
the Th2-type cytokine IL-4 and IL-10, appears to be cen-
tral for the induction and the maintenance of allograft 
tolerance [11, 15]. These findings indicate that Th1-type 
and Th17-type cytokines, that promote allograft rejec-
tion, may compromise pregnancy, whereas the Th2-type 
cytokines inhibiting in particular the Th1 responses, 
promote allograft tolerance and therefore may improve 
pregnancy success. Moreover, T reg cells, which dampen 
all the T helper responses has also been reported to be 
responsible for fetal alloantigens tolerance [16] and could 
induce fetoallograft tolerance through the production of 
IL-10 and TGF-β [17]. However recent studies in mice 
suggest that T reg cells play an important role in response 
to semen independently of placental antigen exposure, 
in preparing endometrium for implantation dampening 
uterine inflammation [18].
In mice many evidence confirmed the role of Th1- and 
Th2-type cytokines present at fetomaternal interface 
on the development of pregnancy [19–22]. Studies per-
formed on unexplained recurrent abortion (URA), which 
is characterized by the loss of three or more consecu-
tive pregnancies in the first trimester of pregnancy (with 
normal karyotype of the conceptus) has been chosen as 
model to study the first trimester of human pregnancy. 
Though multiple causes of URA are known (including 
structural, hormonal, infectious, autoimmune and throm-
bophilic causes), after evaluation, roughly half of all cases 
remain unexplained. The URA cases remained unex-
plained shed a light on the potential role of decidual effec-
tor CD4+ T helper on the maintenance of pregnancy.
Indeed, we reported a defect of IL-4 production by 
both CD4+  and CD8+  T cell clones and a defect of 
IL-10 by CD4+ T cell clones generated from the decidua 
of women suffering from URA undergoing a spontane-
ous abortion in comparison with women with successful 
pregnancy [23]. Thus, we found in URA a defective pro-
duction of Th2-type cytokines which are essential for the 
fetal alloantigen tolerance in successful pregnancy. More 
recently, we reported that the purified human decidual 
CD4+ T cells obtained from successful pregnancy, which 
have not been activated in vitro, produce spontaneously 
IL-4, whereas they do never produce IFN-γ spontane-
ously, but only after stimulation with immobilized anti-
CD3 monoclonal antibodies [24]. We also demonstrated 
that the purified CD4+ T cells were previously activated 
by the trophoblast cells in  situ and expressed without 
any additional in  vitro stimulation high levels of activa-
tion markers (CD25, CD69 and HLA-DR) [24]. These 
results confirm the prevalence of Th2 cells activated by 
trophoblast antigens at the feto-maternal interface [23, 
25, 26]. Progesterone, which, at concentrations compara-
ble to those present at the feto-maternal interface during 
pregnancy, is a potent inducer of production of IL-4 [27] 
could be at least in part responsible for a Th2 switch at 
feto-maternal interface.
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Excessive Th17 activity has also been described to pro-
mote spontaneous abortion. Accordingly, Th17 cells has 
been reported to increase in decidua of patients with 
URA compared to healthy pregnant women [28, 29]. 
However, this significant increase seems to occur only 
in inevitable abortion with genital bleeding [29] and was 
suggested to be the consequence rather than the cause of 
miscarriage.
Very recently, we reported that an associated produc-
tion of IL-4 and IL-17 is exhibited by a large number 
of decidual CD4+  T cells (named Th17/Th2 cells) in 
successful pregnancy and at embryo implantation site 
whereas pathogenic decidual Th17/Th1 cells are preva-
lent in URA and far from the embryo implantation site 
[10]. The differentiation of Th17 cells into Th17/Th2 cells 
is due to soluble HLA-G5, the soluble isoform of HLA-G, 
a non polymorphic Class I molecule produced by embryo 
and trophoblast cells in normal human pregnancy [10]. 
Thus, it seems that Th17 cells do not show a pathogenic 
role for pregnancy, but a beneficial role, when they also 
produce IL-4 whereas Th17/Th1 are pathogenic for preg-
nancy. In the intrauterine environment (both fetal and 
amniotic compartments) infection-related immunity 
seems to be preferentially directed towards combating 
extracellular microbial pathogens (responsible for a five 
fold increase of fetal resorption) with Th17-mediated 
immune responses [30] suggesting that Th17/Th2 cells 
could be essential for the success of pregnancy, because 
they may promote an adequate response to protect the 
mother against dangerous extracellular pathogens and 
induce fetoallograft tolerance together with Th2 cells and 
T reg cells.
Thus, T cells functions exacerbated during pregnancy 
characterized by a tolerogenic Th2-type profile, could 
have an influence on autoimmune disease improvement 
or worsening.
Autoimmunity is related to T cell 
mediated‑responses
CD4+  T helper cells are critical for proper immune 
cell homeostasis and host defense, but are also major 
contributors to pathology of autoimmune and inflam-
matory diseases. Since the discovery of the Th1/Th2 
dichotomy, many additional Th subsets were discovered, 
each with a unique cytokine profile, functional proper-
ties, and presumed role in autoimmune tissue pathol-
ogy. This includes principally Th1, Th2, Th17 and Treg 
cells which are characterized by specific cytokine pro-
files described above. Cytokines, which are often cat-
egorized into pro-inflammatory and anti-inflammatory 
produced by these T helper subsets play a critical role 
in directing the effector response. The different T helper 
subsets in terms of cytokine profiles influence and shape 
the immune response, and could promote autoimmune 
and inflammatory diseases [31]. Therefore, autoim-
mune diseases develop as a result of abnormalities in 
immune response mediated by activated T cells-derived 
cytokines. Accordingly, IFN-γ produced by Th1 cells, has 
long been associated with pathology of several autoim-
mune diseases including autoimmune type 1 diabetes, 
multiple sclerosis (MS) and rheumatoid arthritis (RA). 
The association IFN-γ and autoimmune disorders is not 
surprising because IFN-γ is a potent proinflammatory 
cytokine which has a number of important roles includ-
ing, increasing major histocompatibility gene complex 
(MHC) class I (MHC-I) and class II (MHC-II) antigen 
presentation, increasing the expression of toll-like recep-
tors (TLR) by innate immune cells, promoting immu-
noglobulin G class switching, promoting the induction 
of chemokine secretion, macrophage activation and 
increased phagocytosis. Even before the discovery of Th1 
cells, evidence for IFN-γ having detrimental effects on 
autoimmune diseases was provided by the observation 
that administration of IFN-γ to MS patients was deleteri-
ous and resulted in exacerbation of the disease [32].
However, there is some debate whether Th1 cells 
only play a pathogenic role in autoimmune diseases, 
or whether they also contribute to protective/anti-
inflammatory immune responses. Experimental allergic 
encephalomyelitis (EAE) is an animal model of inflam-
matory demyelinating disease of the central nervous sys-
tem. It is widely studied as an animal model of the human 
central nervous system demyelinating diseases, includ-
ing MS. Experiments testing the impact of genetic dele-
tion of IFN-γ on EAE showed that animals lacking IFN-γ 
developed disease with increased severity compared with 
IFN-γ sufficient controls [33]. Several hypotheses have 
been proposed to account for the apparent anti-inflam-
matory properties of IFN-γ including the downregulation 
of lymphocyte trafficking into the draining lymph-nodes 
[34], the control of T cell clonal expansion via induc-
tion of apoptosis [35] and the induction of indoleamine 
2,3-dioxygenase (IDO), which exerts anti-inflammatory 
effects in lymph nodes and tissues [36].
Another T helper subset characterized by the produc-
tion of IL-4, IL-5 and IL-13, the Th2 subset can promote 
pathology of several different autoimmune diseases, 
particularly those which are associated with humoral 
immune responses. Indeed, studies have demonstrated 
that aberrant and continued IL-4 expression in vivo can 
rescue autoreactive B cells from apoptosis, enhance their 
survival, and induce activation of autoreactive B cells and 
thereby promote autoimmune diseases [37]. Additionally, 
even in Th1 mediated immunopathology, Th2 cells may 
induce the generation of autoantibodies and enhance 
pathology. In contrast, Th2-type cytokines can mediate 
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protection either by directly suppressing Th1/Th17 devel-
opment via IL-4/IL-13 respectively, or by counteracting 
Th1-mediated inflammation. IL-4 is known to strongly 
suppress the development of Th1 cells even in an envi-
ronment with high levels of IFN-γ, thereby antagonizing 
Th1 cell functions [38]. Anti-inflammatory properties of 
IL-4 include the inhibition of Th1-activated macrophages 
and suppression of the secretion of several potent pro-
inflammatory mediators including IL-1, TNF and reac-
tive oxygen species (ROS).
Even prior to the discovery of Th17 cells, which pro-
duce IL-17A, IL-17F and IL-22, IL-17 was noted to be 
overexpressed in a number of inflammatory/autoimmune 
conditions including MS [39], RA [40, 41], systemic lupus 
erythematosus (SLE) [42, 43] and airway inflamma-
tory diseases [44] and thus has been implicated in their 
pathogenesis. Models of autoimmune diseases have sub-
stantiated Th17 cells as important contributors to tissue 
pathology and to the promotion of antibody responses. 
Much of the pathogenic functions of Th17 cells have been 
attributed to the secretion of IL-17, including the induc-
tion of the release of proinflammatory cytokines includ-
ing TNF-α and IL-1β, the enhancing B cell functions, the 
recruitment of neutrophils and the activation of innate 
immune cells. Moreover, IL-17 induces the secretion 
of chemokines and other inflammatory mediators, the 
expression of adhesion molecule (ICAM-1), prostaglan-
din E2, as well as promoting tissue damage through the 
induction of matrix metalloproteinases and antimicro-
bial-peptides. In fact, increased IL-17 production sus-
tains a pro-inflammatory environment and can cause 
excessive tissue damage [45]. Recently, it has been sug-
gested that Th17 cells that have shifted towards Th1-phe-
notype seem to be more aggressive and more pathogenic 
than Th17 unshifted cells particularly in inflammatory 
diseases as MS, RA, psoriasis or inflammatory bowel dis-
eases. Nonetheless, IL-17 could be dispensable for the 
development of organ-specific autoimmunity, as in EAE 
[46]. Although IL-17 could be dispensable, IL-23, which 
promotes the stability of Th17 cells, and T-bet, key tran-
scription factor of Th1 cells, which regulates the expres-
sion of IL-23 receptor, are essential for autoimmune 
disorders.
Very recently, the newly identified T helper cell 22 
(Th22) has been involved in autoimmune diseases patho-
genesis. Th22 is a subset of CD4+  T helper cells obvi-
ously discrete from Th17 and Th1 subsets by production 
of interleukin (IL)-22 but not IL-17 or IFN-γ, and also 
with distinguished expression of aryl hydrocarbon recep-
tor (AHR) as the key transcription factor. This T helper 
subset, by producing pro-inflammatory cytokines such as 
IL-22 and tumor necrosis factor-α (TNF-α), is implicated 
in the pathogenesis of autoimmune disease including RA, 
SLE, Behçet’s disease, type 1 diabetes, immune throm-
bocytopenia [47], psoriasis and MS [48]. Thereby, Th22 
cells and in particular IL-22 are implicated as a potential 
therapeutic target in autoimmune diseases.
Finally, not only Th1, Th2, Th17 and Th22 cells have 
been implicated in the pathogenesis of autoimmune 
disorders, the new subset follicular helper T cells (Tfh) 
seems to have a role in the pathogenesis of different auto-
immune disorders [49]. Tfh has many features in com-
mon with Th17 cells, such as the ability to produce IL-21 
and to express the IL-23 receptor (IL23R), the inducible 
co-stimulatory molecule ICOS, and the transcription fac-
tor c-Maf, all of them essential for expansion and estab-
lishment of the final pool of both Th17 and Th22 subsets. 
Tfh cells differ from Th17 by their ability to home to B 
cell areas in secondary lymphoid tissue through interac-
tions mediated by the chemokine receptor CXCR5 that 
they express, and its ligand CXCL13. These CXCR5+ 
CD4+ T cells are considered an effector T cell type spe-
cialized in B cell help. The role of Tfh cells and its primary 
product, IL-21, on B cell activation and differentiation is 
essential for humoral immunity against infectious agents. 
However, when deregulated, Tfh cells seem to contribute 
to exacerbated humoral response and autoantibody pro-
duction in autoimmune diseases. Accordingly, the pres-
ence of circulating Tfh cells as a potential biomarker of 
disease has been studied in various autoimmune condi-
tions, including myasthenia gravis (MG), autoimmune 
thyroiditis, Sjögren’s syndrome (SS), RA, MS, SLE, ulcer-
ative colitis, Crohn’s disease, ankylosing spondylitis, type 
1 diabetes mellitus, autoimmune hepatitis, primary bil-
iary cirrhosis and juvenile dermatomyositis. Alteration 
of Tfh cells have been reported in patients with various 
autoimmune diseases, such as RA, SLE and autoimmune 
thyroid diseases, where Tfh cells are present at increased 
frequency and show positive correlation with serum 
autoantibody titer. Therefore, a better understanding of 
the biology and the roles of Tfh cells is expected to con-
tribute in clarifying the role of this subset in the patho-
genesis of autoimmune disorders [49].
Some cytokines produced by non-T cells could stimu-
late the inappropriate activities of cells implicated in the 
pathogenesis of autoimmune diseases. Interleukin-27 
(IL-27) is a member of the IL-12 family, is produced by 
activated antigen-presenting cells and plays an impor-
tant role in the regulation of CD4+ T cell differentiation 
and immune response. IL-27 activates multiple signaling 
cascades, including the JAK-STAT and p38 MAPK path-
ways. Several studies have revealed that IL-27 promotes 
the differentiation of Th1 and Tr1, but inhibits Th2, Th17, 
and Treg cells. IL-27 displays both pro- and anti-inflam-
matory activities in different autoimmune diseases. The 
pro-/anti-inflammatory activity of IL-27 is influenced 
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by the underlying immune effector pathways, the phase 
of the disease, the presence or absence of counter-regu-
latory cytokines/T cell subsets, and the tissue/cell type 
under study. Meka et al. [50] discussed the role of IL-27 
in RA, MS, colitis, SLE, psoriasis, type 1 diabetes, and 
uveitis. Most of this information is derived from experi-
mental models of these autoimmune diseases.
Despite a spectrum of outcomes in various auto-
immune diseases, mostly anti-inflammatory and 
immunomodulatory effects of T cell cytokines have 
been observed in these disorders. Accordingly, T cell 
cytokines, but also inducers/inhibitors of some T cell-
secreted cytokines represent a novel, promising target/
agent for the treatment of autoimmune diseases.
T cell responses in autoimmune disorders are 
influenced by pregnancy
In the light of what described before, Th1 and Th17-type 
autoimmune disorders could be improved when there 
is a rise in Th2-type cytokines in pregnancy (e.g. RA, 
Graves disease and MS [51–54]) and Th2-type autoim-
mune disorders could get worse in pregnancy when Th2-
type cytokines increased (e.g. SLE [55]). By contrast, in 
the post partum period, when the Th2-type cytokines 
decreases Th1 and Th17-type inflammatory and auto-
immune disorders could get worse and Th2-type auto-
immune disorders could improve. As the matter of fact, 
during pregnancy, SLE flares are associated with anti-
phospholipids (aPL) antibodies, synergic changes of 
pregnancy on Th1 and Th2 cytokines, that interact with 
hormones such as estrogen and prolactin that amplify 
the inflammatory effect. From the clinical point of view, 
SLE activity at pregnancy onset, thrombocytopenia, 
lupus nephritis, arterial hypertension, aPL syndromes, 
preeclampsia is associated with lupus flares and fetal 
complications. The SLE flares during pregnancy make 
the difference between an uncomplicated pregnancy 
and pregnancy with maternal and fetal complications 
[55]. Pregnancy and the postpartum period have a pro-
found effect not only on SLE, but also on autoimmune 
thyroid disease. Graves disease ameliorates during preg-
nancy, only to relapse postpartum, whereas postpartum 
thyroiditis is caused by destructive thyroiditis during the 
first few months after delivery [51]. Similarly, pregnant 
women with MS typically have a greatly reduced relapse 
rate, whereas very soon after the delivery, the disease 
activity returns, often even at a higher level than seen in 
the pre-pregnancy year. The reasons for the increased 
postpartum activity are not entirely clear, but factors such 
as the abrupt decrease in estrogen levels immediately 
after the delivery and the loss of the immunosuppressive 
state of pregnancy are likely of importance [54]. There 
is compelling evidence that estrogen, progesterone, and 
testosterone control autoimmune disorders. In particu-
lar these hormones control MS by influencing immune 
responses and by contributing to repair mechanisms 
in the nervous system. Similarly to many other autoim-
mune diseases, MS is more common among women than 
men, and its incidence among women is rising. There are 
also qualitative differences in the disease course between 
men and women, with male patients experiencing 
increased disease progression, brain atrophy and cogni-
tive impairment.
Hormones, which seems to contribute to autoimmune 
disorders worsening or improvement by influencing T 
cell cytokine responses involved in the pathogenesis of 
these disorders, may offer important insights into auto-
immune disease prevention and treatment (Table 1).
Hormone‑controlled T cell cytokine profile 
influences progression of autoimmune 
and inflammatory diseases
Women mount more vigorous antibody- and cell-medi-
ated immune responses following either infection or 
vaccination than men. A large number of autoimmune 
diseases are more prevalent in women. Thus, it seems 
that sex influences susceptibility to autoimmune dis-
eases (e.g. RA, for which the female-to-male ratio is 3:1 
has been reported [56]). Many ideas mainly based on 
hormonal and genetic factors that influence the autoim-
mune systems of females and males differently, have been 
proposed to explain this predominance. These hypoth-
eses have gained credence mostly because many of these 
diseases appear or fluctuate when there are hormonal 
changes such as in late adolescence and pregnancy. Dif-
ferences in X chromosome characteristics between 
men and women with an autoimmune disease have led 
researchers to think that the genetic background of this 
group of diseases also relates to the genetic determi-
nants of gender. Thus, the hormonal changes as well as 
the genetic factors, could explain why women are more 
prone to develop autoimmune diseases [57].
Table 1 Pregnancy influences autoimmune diseases pro‑
gression
During pregnancy Th2-type autoimmune disease get worsen and Th1/Th17-type 
autoimmune disease improved
Autoimmune disease Influence on pregnancy
Rheumatoid arthritis (RA) Improved
Systemic lupus erythematosus (SLE) Worse
Multiple sclerosis (MS) Improved
Graves’ disease Improved
Systemic sclerosis (SS) Worse
Hashimoto thyroiditis Improved
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Female hormonal stimulation of immune responses 
could be responsible for the higher incidence of most 
autoimmune diseases in women than in men. Prior the 
discovery of Th17 cells, the first evidence of the role of 
hormonal changes on the autoimmune disorders pro-
gression derived from studies performed on Th1- and 
Th2- type cells. Indeed, it has been demonstrated that 
both androgens and estrogens are able to regulate the 
Th1/Th2 balance. Androgens were described as hor-
mones which promote autoimmune diseases with a pro-
file of Th1-type cytokines, such as RA, whereas estrogens 
were described as inducers of autoimmune diseases with 
a Th2-type cytokine profile, like  SLE. Thus, Th1-type 
autoimmune diseases could be improved when decrease 
Th1-type cytokines, or when there is a rise in Th2-type 
cytokines (increased estrogens, as in pregnancy), whereas 
Th2-type autoimmune diseases could be improved when 
Th2-type cytokines are diminished (decreased estrogen, 
as in post-partum period) or when Th1-type response is 
stimulated [58].
This idea has gained credence because, in particular 
for RA, the peak incidence in women coincides with the 
time of menopause, when estrogen levels rapidly drop, 
connecting sex hormones to disease etiology [59]. In 
contrast, men have rather continuous levels of estrogen 
throughout their adult lives, and estrogen levels are lower 
in postmenopausal women than in men of correspond-
ing age [60]. In a well-established experimental model of 
RA, the collagen-induced arthritis (CIA), it has repeat-
edly been shown that estrogen ameliorates disease devel-
opment [61, 62]. In contrast to RA, estrogen aggravates 
systemic lupus erythematosus [63]. Estrogen is a potent 
immunomodulatory agent and can exert stimulatory as 
well as regulatory effects on the immune system, such as 
enhancing B cell antibody production, reducing B and T 
lymphopoiesis and inhibiting T cell-dependent inflam-
mation [64, 65].
More recently with the discovery of Th17 cells, RA has 
been associated as MS, to Th17-mediated inflammatory 
diseases. Effects of estrogen on Th17 cells have mostly 
been studied in the context of the experimental MS, 
called EAE, where an estrogen is protective. Estrogen 
decreases production of IL-17 in EAE and inhibits Th17 
differentiation and disease progression, dependent on 
estrogen receptor α (ERα) in T cells [66]. Furthermore, 
the regulatory role of estrogen has been demonstrated in 
CIA, where the estrogen metabolite 2-methoxyestradiol 
decreased IL-17 mRNA in arthritic joints [67], regulates 
the localization of Th17 cells, resulting in increased Th17 
in lymph nodes but decreased Th17 in joints of CIA [56].
Progesterone is also able to decrease the Th17 cell 
activity [68] and could decrease the progression of IL-
17-mediated autoimmune and inflammatory diseases. 
Progesterone is also a potent Th2-inducer [27] that could 
influence the progression of Th2 and Th1-mediated 
autoimmune disorders, by worsening Th2-type autoim-
mune disorders and improving Th1-mediated autoim-
mune and Th17/Th1-mediated inflammatory disorders. 
During pregnancy, the rise in Th2-type cytokines could 
be mostly due to progesterone, which is 10- to 50-fold 
higher at feto-maternal interface than in peripheral blood 
and which can inhibit the development and function of 
Th1 and macrophages cells [69], thus preventing the 
trophoblast alloantigen rejection.
Therefore, during pregnancy, hormonal changes 
which could play a critical role in determining the effec-
tor CD4+  T cell cytokine profile at fetomaternal inter-
face, could explain why in some conditions pregnant 
women are more prone to develop Th2-type autoim-
mune diseases, whereas in pregnant women the Th1- and 
Th17-type autoimmune and inflammatory diseases are 
improved (Fig. 1).
Conclusion
The immunology of pregnancy underlies the role of 
CD4+ T cell cytokine profile. Indeed, the mother must 
maintain tolerance of the fetal semi-allograft while not 
suppressing her own immune system and exposing 
herself and the fetus to infection. Non-specific factors, 
including probably not only hormonal changes [26, 27, 
70], but also trophoblast key immunomodulatory mol-
ecules (e.g. HLA-G5, [10]) favoring a switch to a pre-
dominantly Th2-type cytokine profile, may play some 
part in the maintenance of transient tolerance to pater-
nal antigens in pregnancy [23, 25, 26]. The generation of 
specific Th2 and Th17/Th2 cells and T reg cells, is key 
to the maintenance of pregnancy. These cells preferen-
tially accumulate in the decidua but may also be present 
T cell
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IL-4
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autoimmune 
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• RA
• MS
• Graves’        
disease
• Hashimoto
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Estrogens
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Fig. 1 Hormone‑controlled T cell responses influence the progres‑
sion of autoimmune diseases: progesterone and estrogens inducing 
Th2‑type response and decreasing Th1/Th17 response influence the 
improvement and the worsening of Th1/Th17‑type autoimmune 
diseases, and Th2‑type autoimmune diseases, respectively
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in the mother’s circulation and are thus capable of regu-
lating coincidental autoimmune responses to remission 
or worsening of the related Th1-/Th17- or Th2-autoim-
mune diseases, respectively [51]. The postpartum exac-
erbation of some Th1/Th17 autoimmune disorders may 
reflect an imbalance in Th2-type cells and T reg cells, 
which is caused by the rapid fall in the numbers of these 
cells after delivery.
Autoimmune disorder development could also 
be influenced by the transplacental transfer of cells 
between mother and fetus, which occurred during 
pregnancy even years before the onset of the disorder. 
The fetal microchimerism is acquired by the mother 
during pregnancy and this fetal cells are maintained 
in the mother for decades. Similarly, there is also a 
maternal microchimerism acquired by an infant dur-
ing pregnancy. In mouse models it is possible to study 
the bi-directional transfer of cells in pregnancy using 
fluorescent tags. Years ago, we showed that systemic 
sclerosis (SSc), an immunologically mediated dis-
order of the connective tissue, is characterized by a 
predominant activation of IL-4-producing Th2 cells, 
which may account for the clinical and serological 
similarities of SSc to chronic graft versus host disease 
(cGVHD), in which T cells from involved tissues pro-
duce Th2-type cytokines. We showed that offspring 
CD4+ T cells present in the blood and skin of women 
with SSc are able react with maternal MHC antigen and 
exhibit a Th2-type profile, supporting the possibility 
that cGVHD reaction attributable to long-term micro-
chimerism plays a pathogenic role of SSc [71, 72]. The 
fetal microchimerism has been described in many other 
autoimmune diseases [73]. More recently, it has been 
demonstrated that maternal microchimerism could play 
a role in type 1 diabetes of children [74].
Therefore, pregnancy is able to influence the onset and 
progression of autoimmune and inflammatory diseases 
by influencing the T cell cytokine-mediated responses 
during the gestation period, the post-partum period, but 
also decades after the pregnancy period.
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